Danish drugmaker Genmab said on Friday that its experimental drug for a type of blood cancer failed to meet the main goal in a late-stage study.

Eli Lilly (LLY) heads into 2026 with GLP-1 pricing and competition risks; oral GLP-1 race heats up and downside looms.

Nurix advances CLL therapy with NX-5948 showing 83% response, 22.1-month PFS, $680M cash, and $3B risk-adjusted sales ...

Some women adopted non-Jewish identities to support the resistance. For most, though, it was simply a strategy for survival – ...

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug review voucher.

Marvel actress Evangeline Lilly has revealed that she’s suffering from brain damage after fainting and hitting her head on a ...

Calla Lilly on The Masked Singer season 14 remains unmasked, but clues about a life-threatening diagnosis, three children, ...

Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's ...

In this week’s edition of InnovationRx, we look at a ‘holy grail’ pill for sleep apnea, Pomelo Care’s expansion, Nvidia and ...

A more detailed review of data by the FDA showed that GLP-1 drugs do not increase the risk of suicidal ideation or behavior.

The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted ...

In the last few months of 2025, shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) went on an undeniable hot ...